Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879583 | 1.00 | KMT2A (0.37) | KMT2AHSD11B1LMNAALDH1A1KDM4E | |
| SCHEMBL4875497 | 0.91 | KMT2A (0.40) | KMT2AHSD11B1LMNAALDH1A1TSHR | |
| SCHEMBL4875500 | 0.91 | KMT2A (0.40) | KMT2AHSD11B1LMNAALDH1A1TSHR | |
| SCHEMBL5182709 | 0.90 | P2RX7 (0.38) | KMT2AHSD11B1ACKR3GPR6 | |
| SCHEMBL5182706 | 0.90 | P2RX7 (0.38) | KMT2AHSD11B1ACKR3GPR6 | |
| SCHEMBL4877654 | 0.90 | HSD11B1 (0.35) | KMT2AHSD11B1LMNAALDH1A1KDM4E | |
| SCHEMBL4877659 | 0.90 | HSD11B1 (0.35) | KMT2AHSD11B1LMNAALDH1A1KDM4E | |
| SCHEMBL4874077 | 0.88 | KMT2A (0.38) | KMT2AHSD11B1LMNAALDH1A1TSHR | |
| SCHEMBL4874083 | 0.88 | KMT2A (0.38) | KMT2AHSD11B1LMNAALDH1A1TSHR | |
| SCHEMBL4868793 | 0.86 | KMT2A (0.41) | KMT2AACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | KMT2A 3886/4885HSD11B1 544/4885LMNA 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.